Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Binocrit epoetin alfa: Phase III data

In a double-blind, 28-week Phase III trial in 479 patients, HX575, a biosimilar version of epoetin

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE